Healthcare Services

Neurotrophic Keratitis Treatment Market Industry Forecast Reflecting Growth To $6.78 Billion By 2030

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Neurotrophic Keratitis Treatment Market In 2026 And 2030?

The neurotrophic keratitis treatment market size has experienced substantial growth in recent years. This market is anticipated to expand from $1.47 billion in 2025 to $1.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 36.1%. Key drivers for this historic growth include the rising prevalence of diabetes-related corneal disorders, an uptick in herpes simplex eye infections, the emergence of more ophthalmology specialty clinics, greater clinician awareness of neurotrophic keratitis, and the expansion of hospital-based eye care services.

The neurotrophic keratitis treatment market is anticipated to experience substantial growth in the coming years, projected to reach $6.78 billion by 2030, exhibiting a robust compound annual growth rate (CAGR) of 35.8%. This expansion during the forecast period is driven by advancements in regenerative ophthalmic therapies, the increasing approval of rhNGF-based drugs, an expanding aging population at risk of nerve degeneration, growing investment in rare eye disease research, and broadening access to advanced eye care in emerging markets. Significant trends for this period include the rising adoption of recombinant human nerve growth factor therapies, a growing preference for minimally invasive corneal repair procedures, an increased emphasis on early-stage diagnosis and intervention, the expansion of homecare-based ophthalmic treatment solutions, and advancements in amniotic membrane preservation techniques.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp

What Core Drivers Are Transforming The Neurotrophic Keratitis Treatment Market?

The escalating occurrence of eye diseases is projected to drive the expansion of the neurotrophic keratitis treatment market moving forward. Eye conditions encompass a broad spectrum of ailments impacting the structure and function of the eyes, often leading to compromised vision or blindness. This increase in eye disease prevalence is influenced by factors such as an aging population, evolving lifestyles, and a higher incidence of chronic conditions like diabetes. Neurotrophic keratitis treatment plays a role in supporting ocular health by enhancing corneal sensation, accelerating the healing process, warding off infection, and easing discomfort. For instance, in August 2023, the World Health Organization (WHO), a Switzerland-based United Nations agency, reported global estimates indicating that 2.2 billion people suffer from near or distance vision impairment. This figure includes 1 billion cases that are either preventable or have not received treatment, with refractive errors and cataracts remaining the foremost global contributors to vision loss. Furthermore, only 36% of individuals experiencing distance impairment due to refractive errors and just 17% of those with cataract-related impairment have obtained proper care. Therefore, the rising prevalence of eye diseases is a key factor propelling the growth of the neurotrophic keratitis treatment market.

What Segment Categories Are Evaluated In The Neurotrophic Keratitis Treatment Market Study?

The neurotrophic keratitis treatment market covered in this report is segmented –

1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments

2) By Route Of Administration: Oral, Topical, Other Routes Of Administrations

3) By Application: Stage I, Stage II, Stage III

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics

2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution

3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane

4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty

5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses

Which Trends Are Shaping The Neurotrophic Keratitis Treatment Market Landscape?

Leading companies within the neurotechnology market are concentrating on developing sophisticated therapeutic remedies, such as the endovascular brain-computer interface (BCI), to boost cognitive capabilities and restore movement for patients experiencing neurological impairments. This endovascular BCI provides direct neural access through blood vessels, thereby enhancing interaction and treatment possibilities for individuals with neurological disorders. For example, in April 2024, Synchron’s, a Sweden-based software company specializing in advanced synchronization technologies for data management, unveiled a Patient Registry for its Stentrode Brain Computer Interface. The Synchron Stentrode BCI technology is engineered to interpret brain signals and re-establish motor intent, allowing people with limited mobility to operate digital devices hands-free. This device is implanted via a non-invasive endovascular procedure and wirelessly sends motor intent from the brain, enabling severely paralyzed patients to reclaim independence. This pioneering technology signifies a major improvement in assistive solutions, bettering daily functions like communication and access to crucial services.

Which Organizations Are Operating Within The Neurotrophic Keratitis Treatment Market?

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV

Access The Complete Neurotrophic Keratitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Which Region Has The Strongest Presence In The Neurotrophic Keratitis Treatment Market?

North America was the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in the neurotrophic keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurotrophic Keratitis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12968&type=smp

Browse Through More Reports Similar to the Global Neurotrophic Keratitis Treatment Market 2026, By The Business Research Company

Neuroscience Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Neuroprosthetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuromodulation Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuromodulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795